Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without ...

In children with T-lymphoblastic lymphoma, having an MRD status of less than 0.1% may lead to more time without their cancer worsening or coming back. Having less than 0.1% of minimal residual disease ...

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology ...

Please provide your email address to receive an email when new articles are posted on . The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young ...

Sociodemographic factors affecting survival in stage IIIA NSCLC treated with surgery-based treatment or definitive chemoradiation with immunotherapy consolidation: An NCDB analysis. Disparities in ...

A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). This is an ASCO Meeting Abstract from the 2023 ...

T-cell non-Hodgkin lymphoma (NHL) is a rare form of cancer that affects certain white blood cells called T cells. There are several types of T-cell NHL, each with a unique presentation and outlook.

Pediatric non-Hodgkin’s lymphoma (NHL) is a type of cancer that may affect children. It occurs when cells in the immune system divide uncontrollably. Symptoms can depend on where the cancer develops.